Please login to the form below

Not currently logged in
Email:
Password:

Nektar Therapeutics appoints Jeff Ajer

He joins as an independent director

California, US-based Nektar Therapeutics has appointed Jeff Ajer as its independent director to the company’s board of directors, following his 25 years’ of biotechnology and industry experience.

Ajer’s expertise includes driving commercial operations within rare diseases and speciality medicines and he joins the group from BioMarin, where he served as an executive vice president and chief commercial officer.

There he worked on establishing BioMarin’s global footprint and commercial infrastructure and has played a leadership role in the launches and growth strategies for brands including Brineura, Vimizim, Kuvan and Naglazyme.

He said: “I am honoured to join Nektar’s board during an exciting time in the company’s evolution and growth.

“Over the course of my career, I have had the great pleasure of shaping the growth strategies for various commercial brands across a variety of disease state, and I look forward to leveraging these experiences for Nektar as a new board member.”

Prior to BioMarin, Ajer served as vice president, global transplant operations at Genzyme Corporation, and has held roles in sales, marketing and operations at SangStat Medical Corporation and ICN Pharmaceuticals.

Howard Robin, president and CEO, Nektar Therapeutics, said: “Jeff’s extensive leadership experience within rapidly growing biotechnology companies is a great addition to our board as we continue to build Nektar’s wholly-owned pipeline of innovative drug candidates.

“This appointment adds to the existing expertise of our highly-respected board members as they guide Nektar toward continued growth and success.”

29th September 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics